New hormonal therapies for castration-resistant prostate cancer - Abstract

Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D4-100, Seattle, WA, USA.

 

Continued activation of the androgen receptor (AR) axis despite castration remains a critical force in the development of castration-resistant prostate cancer (CRPC). Therapeutic strategies designed to more effectively ablate tumoral androgen activity are required to improve clinical efficacy and prevent disease progression. Tumor-based alterations in expression and activity of the AR and in steroidogenic pathways mediating ligand generation facilitate the development of CRPC. This article reviews AR and ligand-dependent mechanisms underlying CRPC progression and the status of novel hormonal therapies targeting the AR axis that are currently in clinical and preclinical development.

Written by:
Mostaghel EA, Plymate S.   Are you the author?

Reference: Endocrinol Metab Clin North Am. 2011 Sep;40(3):625-42.
doi: 10.1016/j.ecl.2011.05.013

PubMed Abstract
PMID: 21889725

UroToday.com Prostate Cancer Section

 

 

email news signup